Group 1 - The core point of the article is that *ST Bio is planning to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements after the transaction is completed [2] Group 2 - For the fiscal year 2024, *ST Bio's revenue composition is as follows: 73.32% from the stem cell industry, 26.54% from energy-saving technology services, and 0.14% from other industries [2]

Group 1 - The company *ST Bio (000504) announced on August 11 that it is planning to acquire 51% equity of Hunan Huize Biomedical Technology Co., Ltd. (referred to as "Huize Pharma") in cash [1] - Upon completion of the transaction, Huize Pharma will become a subsidiary controlled by the company [1] - The preliminary assessment indicates that this transaction is expected to constitute a significant asset restructuring [1]

Overview of the Transaction - The company plans to acquire 51% equity of Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements [1][2] - The acquisition aims to enhance the company's industrial chain layout by leveraging Huize's technology and customer resources in drug research and clinical evaluation, which are highly synergistic with the company's existing biopharmaceutical business [2][10] - The agreement signed is a preliminary intention agreement and does not involve specific contract amounts; it is subject to further negotiation and due diligence [2][9] Parties Involved - The transferors include individuals and partnerships that do not have any related party relationships with the company and are not listed as dishonest executors [3][4][5] Target Company Information - Hunan Huize Biomedical Technology Co., Ltd. is a specialized CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services [5][6] - The company has established long-term partnerships with over 300 domestic and international pharmaceutical companies and research institutions, completing more than 1,000 technical service projects [6][10] Financial and Operational Aspects - The registered capital of Huize is approximately 11.1 million yuan, and it has been recognized as a national high-tech enterprise and a key "little giant" enterprise [5][6] - The main business includes drug wholesale and retail, clinical trial services, and various technical services related to medical research and development [5][6] Purpose and Impact of the Acquisition - The acquisition is expected to enhance the company's biopharmaceutical segment, improve profitability, and strengthen risk resistance [10] - It will also integrate clinical transformation research and drug development, leading to improved operational efficiency and significant synergies [10] - Overall, the transaction is aligned with the company's strategic development needs and aims to foster long-term sustainable growth [10]

Core Viewpoint - The company is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements after the transaction is completed [1] Group 1: Transaction Details - The transaction is currently in the planning stage, and there are uncertainties regarding related matters [1] - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services [1] - This transaction is expected to constitute a significant asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies" [1] Group 2: Impact on Company Structure - The acquisition will not involve the issuance of new shares and will not lead to a change in the company's control [1]

证券代码：000504 证券简称：*ST 生物 公告编号：2025-047 南华生物医药股份有限公司 关于筹划重大资产重组暨签署股权收购意向协议 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 重要提示： 1、南华生物医药股份有限公司（以下简称"公司"或"南华生物"）正在 筹划以现金方式收购湖南慧泽生物医药科技有限公司（以下简称"慧泽医药"或 "标的公司"）51%股权，本次交易完成后，慧泽医药将成为公司控股子公司并 纳入合并报表范围。 2、本次签署的《股权收购意向协议》（以下简称"意向协议"或"本协议"） 系各方就收购事宜达成的初步意向协议，旨在表达各方合作意向，具体的交易方 案及交易条款以各方签署的正式协议为准。本次交易尚处于筹划阶段，相关事项 尚存在不确定性。敬请广大投资者谨慎决策，注意投资风险。 3、本次签署的意向协议涉及的后续事宜，公司将严格按照《公司法》《深 圳证券交易所上市公司规范运作指引》等有关法律法规、规范性文件及《公司章 程》的相关要求，履行后续决策程序和信息披露义务。 4、本次交易不构成关联交易。根据初步测算，本次交易预计构 ...

每经AI快讯，8月11日，*ST生物（000504）(000504.SZ)公告称，公司正在筹划以现金方式收购湖南慧 泽生物医药科技有限公司51%股权，交易完成后，慧泽医药将成为公司控股子公司。本次交易预计构成 重大资产重组，不涉及公司发行股份，亦不会导致公司控制权变更。公司将根据尽职调查、审计及评估 结果进一步协商、谈判。 ...

Core Viewpoint - Nanhua Biopharmaceutical Co., Ltd. plans to acquire 51% equity of Hunan Huize Biopharmaceutical Technology Co., Ltd. through a cash transaction, aiming to enhance its industry chain and establish Huize as a subsidiary [1] Group 1 - The acquisition is expected to strengthen the synergy between Nanhua and Huize, as Huize focuses on drug research and clinical evaluation, which aligns with Nanhua's business [1] - The transaction does not constitute a related party transaction and is anticipated to be classified as a major asset restructuring [1] - The intention agreement is preliminary, and the specific transaction plan is subject to negotiation, indicating uncertainty regarding the finalization of the deal [1] Group 2 - The acquisition will not involve the issuance of shares or changes in control [1] - The company will fulfill its regulatory approval and information disclosure obligations as required [1] - Investors are reminded to be aware of the associated risks [1]

Board Meeting Summary - The first meeting of the 12th Board of Directors of Nanhua Biopharmaceutical Co., Ltd. was held on August 8, 2025, via communication methods, with all 7 directors participating in the voting [1][2] - The board elected Mr. Yang Yun as the chairman of the 12th Board of Directors, with a term starting from the approval date until the end of the board's term [1][2] - The board approved the election of various specialized committee members, including Mr. Yang Yun as the head of the Strategy Committee [1][2] Executive Appointments - Mr. Yang Yun was appointed as the General Manager, with a term aligned with the board's term [2] - Mr. Su Liang was appointed as the Board Secretary, and Mr. Liu Ailong, along with Mr. Lin Pengbin, were appointed as Vice General Managers [2] - The board approved the adjustment of executive compensation standards and performance assessment schemes to enhance management incentives and constraints [2][3] Committee and Regulation Updates - The board approved the revision of the "Audit Committee Work Rules" to align with legal regulations and the company's actual situation [3]

Group 1 - The company *ST Bio (SZ 000504) announced that its 12th first board meeting was held via communication on August 8, 2025, where it reviewed the proposal to amend the "Audit Committee Work Rules" [2] - For the year 2024, the revenue composition of *ST Bio is as follows: stem cell industry accounts for 73.32%, energy-saving technology services account for 26.54%, and other industries account for 0.14% [2]

南华生物医药股份有限公司 审计委员会工作细则 （2025 年 8 月修订） 第一章 总则 第一条 为强化和完善南华生物医药股份有限公司（以下简称"公司"）董 事会决策功能，确保公司董事会对运营管理的有效监督，进一步健全公司的法人 治理结构，根据《中华人民共和国公司法》《上市公司治理准则》《深圳证券交 易所上市公司自律监管指引》等法律法规以及《南华生物医药股份有限公司章程》 （以下简称"公司章程"）等有关规定，公司设立审计委员会，并制定本工作细 则。 第二条 审计委员会是公司董事会按照《公司章程》下设的专门工作机构， 按照《公司章程》和董事会授权勤勉履职，主要负责审核公司财务信息及其披露、 监督及评估内外部审计工作和内部控制。 第三条 董事会办公室负责审计委员会会议的筹备和联络、召开等会议举办 工作。 第四条 内部审计部门为审计委员会下属的日常工作机构，在公司董事会及 其审计委员会的统一领导下开展内部审计工作，并向其负责并报告工作。 第二章 人员组成 第五条 审计委员会成员由三名不在公司担任高级管理人员的董事组成，其 中独立董事应当为过半数并担任召集人，召集人应当为会计专业人士。公司董事 会成员中的职工代表可以 ...